<DOC>
	<DOC>NCT00608712</DOC>
	<brief_summary>Phase IV, open-label, multicenter, non-randomized, with 2 non-comparative investigational arms study, carried out in morbid obesity patients who had undergone gastric bypass surgery for body weight reduction</brief_summary>
	<brief_title>Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Written informed consent signed and dated BMI â‰¥40 kg/m2 or BMI between 35 and 40 kg/m2, but with a severe disease together with obesity Indication for gastric bypass surgery Upper digestive endoscopy prior to surgery not showing esophagitis, erosions, ulcers or neoplasia, examination performed up to 30 days before surgery being considered valid Helicobacter pylori noninfected patients, diagnosed by tests carried out up to 30 days before surgery Contraindication for gastric bypass surgery Contraindication to use Omeprazole and derivatives Patients carriers of gastrinoma or having hypergastrinemia Patients contraindicated to perform UDE Patients with previous esophagogastroduodenal surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>bariatric surgery</keyword>
	<keyword>ulcer prevention</keyword>
</DOC>